Home > Insider Trading > Filing (0001779453-19-000007)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1662774	Cortexyme Inc.	CRTX	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1779451	Chad Boeding	One Lombard Street, Suite 200 San Francisco CA 94111		No	No	No	Yes
1779453	Epiq Capital Group, Llc	One Lombard Street, Suite 200 San Francisco CA 94111		No	No	No	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-08-20	600	$25.69	2,843,210	No	4	P	Indirect	By Mr. Boeding as Trustee for Boeding Family Trust
Common Stock	Acquisiton	2019-08-20	2,310	$25.69	2,845,520	No	4	P	Direct
Common Stock	Acquisiton	2019-08-21	420	$24.87	2,845,940	No	4	P	Indirect	By Mr. Boeding as Trustee of Boeding Family Trust
Common Stock	Acquisiton	2019-08-21	1,635	$24.87	2,847,575	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Mr. Boeding as Trustee for Boeding Family Trust
No	4	P	Direct
No	4	P	Indirect	By Mr. Boeding as Trustee of Boeding Family Trust
No	4	P	Direct

Footnotes

The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.
Beneficially owned directly by Mr. Boeding.
Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/21/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1.